Insmed Inc.'s news that European regulators validated its application for Iplex for children with short stature associated with severe primary insulin-like growth factor 1 deficiency (IGFD) was overshadowed by word of a court ruling in a patent case brought by Tercica Inc. (BioWorld Today)